Willgoos was previously counsel at Paul Hastings.
Willgoos leads trial and appellate teams in Hatch-Waxman and biologic drug litigations concerning blockbuster drugs. She is experienced in cases involving pharmacokinetics and pharmacodynamics, molecular and cellular biology, and drug development, including humanized antibody technology, recombinant DNA vectors, and antidepressant and dermatologic drugs.
The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.
© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.